The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy

Røder, Martin Andreas; Berg, Kasper Drimer; Loft, Mathias; Thomsen, Frederik Birkebæk; Ferrari, Michelle; Kurbegovic, Sorel; Rytgaard, Helene Charlotte; Gruschy, Lisa; Brasso, Klaus; Gerds, Thomas Alexander; Kjær, Andreas; Brooks, James D.; Iversen, Peter

doi:10.1016/j.euf.2016.11.014

Cited by 8 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…48 49 The individual risk of BCR in the first year following enrolment in this study ranged from 2% to 19% and did not change substantially in the period of follow-up. 50 In summary, vaccination against RhoC is a well-tolerated treatment option which induces a long-lasting immune response in the large majority of patients. Vaccinespecific cells are polyfunctional and equipped for an antitumor response.…”

Section: Discussionmentioning

confidence: 99%

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Schuhmacher

Heidu

Balchen³

et al. 2020

J Immunother Cancer

Self Cite

View full text Add to dashboard Cite

BackgroundPeptide-based vaccination is a rational option for immunotherapy of prostate cancer. In this first-in-man phase I/II study, we assessed the safety, tolerability and immunological impact of a synthetic long peptide vaccine targeting Ras homolog gene family member C (RhoC) in patients with prostate cancer. RhoC is a small GTPase overexpressed in advanced solid cancers, metastases and cancer stem cells.MethodsTwenty-two patients who had previously undergone radical prostatectomy received subcutaneous injections of 0.1 mg of a single RhoC-derived 20mer peptide emulsified in Montanide ISA-51 every 2 weeks for the first six times, then five times every 4 weeks for a total treatment time of 30 weeks. The drug safety and vaccine-specific immune responses were assessed during treatment and thereafter within a 13-month follow-up period. Serum level of prostate-specific antigen was measured up to 26 months postvaccination.ResultsMost patients (18 of 21 evaluable) developed a strong CD4 T cell response against the vaccine, which lasted at least 10 months following the last vaccination. Three promiscuouslypresented HLA-class II epitopes were identified. Vaccine-specific CD4 T cells were polyfunctional and effector memory T cells that stably expressed PD-1 (CD279) and OX-40 (CD134), but not LAG-3 (CD223). One CD8 T cell response was detected in addition. The vaccine was well tolerated and no treatment-related adverse events of grade ≥3 were observed.ConclusionTargeting of RhoC induced a potent and long-lasting T cell immunity in the majority of the patients. The study demonstrates an excellent safety and tolerability profile. Vaccination against RhoC could potentially delay or prevent tumor recurrence and metastasis formation.Trial registration numberNCT03199872.

show abstract

Section: Discussionmentioning

confidence: 99%

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Schuhmacher

Heidu

Balchen³

et al. 2020

J Immunother Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Four studies focused on the development and testing of apps [ 18 , 20 , 21 , 23 ]. Zhang et al [ 23 ] presented the MyHealthAvatar app.…”

Section: Resultsmentioning

confidence: 99%

“…Of these, one paper was excluded as it was not relevant and a further five papers were removed as they were based on unpublished or unreleased apps (not available in online stores). This left 13 papers for inclusion in our final review [12][13][14][15][16][17][18][19][20][21][22][23][24] (Fig. 1).…”

Section: Study Selectionmentioning

confidence: 99%

“…The papers included in this review focused on a variety of factors in assessing available apps including readability, quality and accuracy, usage, and app development. A comprehensive summary of the individual studies has been presented in Table 1 Røder et al [21,26] developed and validated the CPC Risk Calculator which estimates the risk of biochemical recurrence following a radical prostatectomy. The authors used preoperative PSA, pT stage, prostatectomy Gleason score, and surgical margin (R) status to develop the nomogram.…”

Section: Description Of Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Do prostate cancer-related mobile phone apps have a role in contemporary prostate cancer management? A systematic review by EAU young academic urologists (YAU) urotechnology group

et al. 2020

View full text Add to dashboard Cite

Aims and objectives To review the available literature regarding the use of prostate cancer-related mobile phone applications (PCA). Materials and methods The search was for English language articles between inceptions of databases to June 2019. Medline, EMBASE, Cochrane Library, CINAHL and Web of Science were searched. Full-text articles were reviewed, and the following data were extracted to aid with app analysis: name of application, developer, platform (Apple App Store or Google Play Store) and factors assessed by the article. Results The search yielded 1825 results of which 13 studies were included in the final review. 44 PCAs were identified from the data collected of which 59% of the PCAs had an educational focus. 11 apps were inactive and 5 weren’t updated within the last year. Five studies focused on the development and testing of apps (MyHealthAvatar, CPC, Rotterdam, Interaktor, NED). Two studies evaluated the readability of PCAs. Most PCAs had a reading level greater than that of the average patient. Two studies evaluated the quality and accuracy of apps. Majority of PCAs were accurate with a wide range of information. The study reported most PCAs to have deficient or insufficient scores for data protection. Two studies evaluated the accuracy of Rotterdam, CORAL and CPC risk calculators. Rotterdam was the best performer. Conclusions PCAs are currently in its infancy and do require further development before widespread integration into existing clinical practise. There are concerns with data protection, high readability standards and lack of information update in current PCAs. If developed appropriately with responsible governance, they do have the potential to play important roles in modern-day prostate cancer management

show abstract

“…ficaram continentes e 86,1% ficaram potentes, neste estudo a continência foi definida pelo não uso de absorvente, e a potência foi definida pela capacidade de manter a ereção durante a relação sexual, não mencionaram em quanto tempo de pós-operatório foi avaliado estas duas complicações e nem se utilizaram os questionários (37) . desenvolvidos relacionados ao CP, dentre eles o aplicativo "Ned" foi desenvolvido com o intuito de integrar os pacientes que "sobreviveram" ao CP (38) , o aplicativo "CPC risk calculator" foi desenvolvido com o objetivo de predizer o risco de recidiva bioquímica pós PR (39) . O "Rotterdam Prostate Cancer Risk Calculator" ajuda a predizer o risco do CP, especialmente aqueles clinicamente significantes (40) .…”

Section: Desenvolvimento Do Aplicativounclassified

Desenvolvimento de aplicativo digital para avaliar resultados funcionais dos pacientes submetidos à prostatectomia radical robótica assistida

Faria¹

View full text Add to dashboard Cite

The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy

Cited by 8 publications

References 25 publications

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial

Do prostate cancer-related mobile phone apps have a role in contemporary prostate cancer management? A systematic review by EAU young academic urologists (YAU) urotechnology group

Desenvolvimento de aplicativo digital para avaliar resultados funcionais dos pacientes submetidos à prostatectomia radical robótica assistida

Contact Info

Product

Resources

About